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The interaction of estrogen receptor a (ERa) with the
consensus LXXLL motifs of transcriptional coactiva-
tors provides an entry for functional ERa inhibi-
tion. Here, synthetic cell-permeable LXXLL peptide
probes are brought forward that allow evaluation of
the interaction of specific recognition motifs with
ERa in the context of the cell. The probes feature a
nona-arginine tag that facilitates cellular entry and
induces probe localization in nucleoli. The nucleoli
localization provides an explicit tool for evaluating
the LXXLL motif interaction with ERa. The probes
compete with coactivators, bind ERa, and recruit it
into the nucleoli. The physical inhibition of the ERa-
coactivator interaction by the probes is shown to
be correlated with the inhibition of ERa-mediated
gene transcription. This chemical biology approach
allows evaluating the ERa-coactivator interaction
and inhibitor binding directly in cells.
INTRODUCTION
Estrogen receptor a (ERa) is a member of the nuclear receptor
superfamily and is an estrogen-inducible transcription factor. In
the normal physiology of the female reproductive system, ERa
regulates the growth and function of such tissues as breast,
uterus, and ovaries. In addition, ERa has been identified as play-
ing a role in many pathological processes, such as breast cancer
(Holst et al., 2007). Because 70% of breast tumors depend on
the stimulatory effect of estrogens, anti-estrogen therapies
have been developed that significantly reduce breast cancer
recurrence (Fisher et al., 2005). However, the long-term effects
of tamoxifen, one of the most successful anti-estrogen drugs,
in metastatic disease are limited to an average of 15 months
(Howell et al., 1995), after which tamoxifen resistance develops
in more than 80% of treated women (Clarke et al., 2001). In the
induction of gene transcription, ERa acts in complex association
with other cellular factors, including coactivators, which are
required for the transcriptional activation process to occur
(McKenna et al., 1999). The most widely studied group of ERa702 Chemistry & Biology 16, 702–711, July 31, 2009 ª2009 Elseviercoactivators includes the p160 protein family, consisting of three
members: SRC-1, Tif-2/GRIP1, and SRC-3/AIB1. The impor-
tance of these coactivators in ERa signaling has been high-
lighted by knockout studies and by the discovery of p160 gene
amplification in ERa-positive breast cancer (Xu et al., 1998,
2000; Mahajan and Samuels, 2005). These p160 coactivators
have the ability to interact with ERa and other nuclear receptors
in a hormone-dependent manner via small hydrophobic and
amphiphatic a-helical peptide sequences with the common
signature motif, LXXLL (L = leucine, and X = any amino acid).
Crystallographic studies showed that this motif, also called
nuclear receptor box (NR box), binds to a hydrophobic cleft on
the ERa ligand binding domain (LBD) surface, under control of
activating ligand (Shiau et al., 1998). p160 coactivators contain
three NR box copies within their central nuclear receptor interac-
tion domain. Although the three leucines in the LXXLL motif are
conserved, the amino acid residues flanking this sequence are
not and specify NR box recognition for a particular nuclear
receptor in cooperation with specificities of the ligand. These
characteristic features have raised the idea that the ERa-coacti-
vator interaction is a specific amendable interface for LXXLL
motif–like inhibitors, preventing transactivation by ERa (Pike
et al., 2000; Hall et al., 2000; Vaz et al., 2008). The formation of
the coactivator binding surface on ERa requires a hormone-
dependent conformational change. Inhibitors of coactivator
binding (ICBs) (Rodriguez et al., 2004) may only bind to
hormone-occupied ERa, thus featuring a different mechanism
than the classic anti-estrogen drugs. These ICBs might thus be
useful in anti-estrogen therapy for patients with tamoxifen-resis-
tant breast cancers or could provide a possibility to target
orphan nuclear receptors for which antagonists are difficult to
identify (Kurebayashi et al., 2004).
Several types of compounds blocking ERa-cofactor interac-
tions have already been developed. The first proof that the
concept of inhibiting ERa-cofactor interactions results in the inhi-
bition of ERa-mediated transcription has been obtained with
LXXLL peptides overexpressed in cells from transfected DNA
constructs (Chang et al., 1999; McInerney et al., 1998; Shao
et al., 2000; Connor et al., 2001; Norris et al., 1999). This finding
has been enforced by the identification and the use of synthetic
ICBs, either peptide based or small molecule (Leduc et al., 2003;
Shao et al., 2004; Rodriguez et al., 2004; Geistlinger et al., 2004;
Galande et al., 2004, 2005; Gunther et al., 2008; Parent et al.,Ltd All rights reserved
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ERa-coactivator binding in biochemical assays, and a selected
set of compounds was also able to inhibit ERa gene transactiva-
tion in cellular assays (Gunther et al., 2008; Parent et al., 2008;
LaFrate et al., 2008). The translation from biochemical studies
on the ERa LBD to cellular activity on the full-length protein is,
however, not trivial. For example, it has been reported that the
conformation of the coactivator binding groove in the full-length
receptor tends to be different from the isolated LBD (Chang et al.,
2005; Bapat and Frail, 2003; Chang and McDonnell, 2002). In
addition, direct binding of inhibitors to ERa in cells and their
capacity to displace coactivators are two processes that are
difficult to observe directly. The process of inhibiting the ERa-co-
activator interaction thus requiresmoremolecular insight. There-
fore, methods need to be developed that directly visualize the
interaction of inhibitors with ERa and provide information on
the resulting ERa inhibition. Here, we show that synthetic cell-
permeable LXXLL-peptide probes with specific localization and
visualization tags are ideal molecular probes to inhibit and eval-
uate ERa-coactivator interactions in living cells and to address
the above-mentioned issues. By use of confocal laser scanning
microscopy (CLSM), these probes can be used to monitor the
association of specific peptide sequences with the full-length
ERa and to evaluate their effects on the assembly of ERa
signaling protein complex within the organized microenviron-
ment of the living cell. The peptide probes feature a nona-argi-
nine tag that ensures efficient cellular entry of the peptides and
induces a specific localization of the peptides into the nucleoli.
This specific property of the peptides is used to evaluate the
affinity of different LXXLL-motif peptides for the ERa. The
peptides bind and translocate ERa into the nucleoli, resulting
in the displacement of ERa from the DNA and coactivators.
Overall, the peptides function as functional inhibitors as they
effectively lower ERa-mediated gene transcription.
RESULTS
Selection and Synthesis of LXXLL-Motif Molecular
Probes
For the generation of molecular probes inhibiting the ERa-coac-
tivator interaction, we selected a set of natural LXXLL-motif
sequences reported to have a high affinity for ERa (Bramlett
et al., 2001) and capable of blocking ERa transcriptional activity
when overexpressed in cells—boxes 1 and 2 of the SRC-1 coac-
tivator protein and boxes 1, 2, and 3 of the Tif-2 coactivator
protein (Table 1). Phage display peptides D2 and D11, which
were previously reported to possess a high affinity for full-length
ERa and to bind at the same coactivator binding surface (Chang
et al., 1999), were also included in the selection (Table 1). The
plasma membrane of mammalian cells is generally impermeable
to the vast majority of peptides and proteins. We therefore
decided to take advantage of the cell-permeable properties of
the nona-arginine (R9) peptide sequence (Futaki et al., 2001;
Tu¨nnemann et al., 2008) and use it as a carrier for the selected
LXXLL peptides. The arginine tags were attached to the peptides
at their C terminus bymeans of peptide synthesis. Tomonitor the
localization of the LXXLL peptides within the cells via immuno-
labeling, they were provided with a biotin epitope connected
via an ethylene glycol linker to the C-terminal part of theChemistry & Biology 1complete peptide. In addition to the LXXLL molecular probes,
two AXXAA-molecular probes, based on SRC-1 Box2 and Tif-2
Box2 and mutated for the recognition motif by alanines, were
also generated as negative control peptides.
The effect of the biotin and nona-arginine tags, incorporated in
the peptides, on the binding to the ERa coactivator binding
surface was evaluated in a biochemical fluorescent polarization
assay with the recombinant LBD of ERa (Figure 1). The assay
measures the displacement of a fluorescein-labeled reference
peptide (SRC-1 box2) by the nonfluorescent LXXLL peptides
under study. The R9 tag alone did not bind to ERa LBD, as
expected. The dose-dependent fluorescence depolarization
curves obtained with peptides SRC-1 Box2 and SRC-1 Box2-
PEG-biotin were overlapping (Figure 1A), showing that the
PEG-biotin spacer does not influence ERa binding. For both
the SRC-1 Box2 and the SRC-1 Box2-R9 peptides and the Tif-
2 Box2 and Tif-2 Box2-R9 peptides, the same binding affinities
were found (Figure 1B), showing that the nona-arginine tag
also does not disturb the capacity of the peptides to bind to ERa.
Cellular Toxicity and Intracellular Distribution
of the Synthetic LXXLL Molecular Probes
To study and evaluate any toxic effects of the synthetic peptide
probes, the viability of cells after an overnight incubation with
increasing concentrations of peptides was tested using the
WST-1 assay (see Table S1 available online) (Berridge et al.,
2005). Peptides conjugated to PEG-biotin but lacking the
nona-arginine tag were found to be toxic on the human cancer
cell line U2OS at concentrations of 1 mM, whereas all of their
nona-arginine counterparts showed toxicity at around 0.1 mM.
The nona-arginine tag alone was found to be less toxic to the
cells. Interestingly, the two peptides SRC-1 Box2-Ala-R9 and
Tif-2 Box2-Ala-R9 mutated for the recognition motif by alanines
were not lethal to cells at concentrations up to 0.6 mM. This
difference in minimal toxic concentration may be explained
by a different sequence-dependent cellular uptake capacity of
these peptides, butmay also be related to their intracellular phar-
macological effects. From the dose-dependent toxicity curves
obtained, we determined the concentrations of peptides that
gave less than 20% of cell death, compared with nontreated
cells (Table S1). These peptide concentrations (0.02–0.07 mM),
were also tested by fluorescent assisted cell sorting (FACS) for
apoptosis induction using the specific fluorescently labeled
apoptotic marker Annexin-V (Bedner et al., 1999). Also in this
assay (data not shown), the nona-arginine peptides induced
less than 20% apoptosis at these concentrations.
Table 1. Sequences of the Selected LXXLL-Motif Peptides
SRC-1 Box1 Y S Q T S H K L V Q L L T T T A E Q Q
SRC-1 Box2 L T E R H K I L H R L L Q E G S P S D
SRC-1 Box2-Ala L T E R H K I A H R A A Q E G S P S D
Tif-2 Box1 S K G Q T K L L Q L L T T K S D
Tif-2 Box2 L K E K H K I L H R L L Q D S S S P V
Tif-2 Box2-Ala L K E K H K I A H R A A Q D S S S P V
Tif-2 Box3 K K K E N A L L R Y L L D K D D T K
D2 G S E P K S R L L E L L S A P V T D V
D11 V E S G S S R F M Q L F M A N D L L T6, 702–711, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 703
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zation Studies of the ERa-LBD Binding
Capacity of the Synthetic Peptides
(A) Representative dose-dependent inhibition
curves of selected peptides for the binding of
a fluorescein-labeled SRC-1 Box2 peptide to the
ERa-LBD.
(B) IC50 values of all tested peptides. Error bars
represent mean ± standard error.The cell-entry and intracellular distributions of the synthetic
peptides were assessed by immunolabeling of cells treated
with the peptides using a fluorescent Cy5-conjugated anti-biotin
antibody. CLSM imaging of these cells revealed that the PEG-
biotin spacer and the LXXLL peptides lacking a nona-arginine
tag did cross the plasma membrane to some extent but clus-
tered into vesicular structures in the cytoplasm (Figure 2).
However, the cellular distribution of the nona-arginine-tagged
molecular probes was completely different, localizing in both
the cytoplasm and the nucleus. In the nucleus, these peptides
were mainly found located at the nucleoli, as anticipated
(Figure 2) because the nucleolar accumulation of such positively
charged peptides has been described elsewhere (Tu¨nnemann
et al., 2006). Because this particular localization at the nucleoli
was not found for the non-R9-tagged peptides, we conclude
that this feature can be exclusively ascribed to the R9 tag.
Also, in accordance with the results of a recent study (Kosuge
et al., 2008), we observed that the concentration of serum
used in the culture medium had a significant impact on the distri-
bution of thesemolecular probes inside cells (data not shown). In
addition, we noticed that supplementing the medium with 10%
of non-heat-inactivated serum could abrogate the cellular
uptake of R9 peptides, which is most likely due to unspecific
binding between the peptides and serum components.
However, this did not occur when the medium was beforehand
heat inactivated, resulting in an efficient cellular uptake.
Binding Capacity of LXXLL Molecular Probes
to ERa in Cells
ERa is typically localized in the nucleus, excluded from the
nucleoli, and its uniform distribution in the nucleoplasm rapidly
changes into a hyperspeckled foci pattern upon the addition of
either agonistic or antagonistic ligands (Stenoien et al., 2000).
When bound to estradiol, ERa associates with specific regions
in the DNA, called estrogen responsive elements (EREs), viazinc-finger motifs present in its DNA binding domain. Inhibiting
peptides expressed from DNA constructs fused to a fluorescent
protein are evenly distributed throughout the nucleus, but also in
the cytoplasm, and are colocalized with ERa upon hormone
addition (Schaufele et al., 2000). We investigated here whether
peptide probes of a synthetic nature and featuring a specific
localization tag are able to interact with ERa as well, when
applied externally to cells, and whether the introduced localiza-
tion tag could be used to evaluate this interaction in a novel
manner. Therefore, U2OS cells transiently transfected with full-
length ERa fused to cyan fluorescent protein (CFP) were incu-
bated with the LXXLL-nona-arginine molecular probes in the
presence of estradiol. The ERa-binding capacity of these
peptides was assessed by colocalization with ERa by CLSM.
When cells were not incubated with the molecular probes, ERa
localized as expected in the nucleoplasm, in punctuated foci
(data not shown). The same ERa distribution was observed in
presence of the nona-arginine tag alone, whereas this peptide
itself was clearly observed into the nucleoli (Figure 3A), indicating
a lack of interaction between the receptor and this peptide.
However, incubating the cells with the peptides SRC-1 Box2-
R9, Tif-2 Box1-R9, Tif-2 Box2-R9, and D2-R9 and, to a lesser
extent, with the peptide Tif-2 Box3-R9 resulted in a clear nuclear
colocalization of these peptides with the estradiol-liganded
ERa into the nucleoli. The affinity of these peptides for ERa is
apparently strong enough to bind to ERa and subsequently to
translocate it to the alternative location in the nucleoli. This effect
occurs in the presence of a concentration of estradiol (106 M)
that normally would result in complete recruitment of ERa to
DNA templates. The incorporated nona-arginine tag thus serves
both to facilitate cellular uptake of the peptide probes and as
a specific localization tag, generating a spacial resolution
within the nucleus that enables visualization of peptides/ERa
complexes. Using the statistic tools of the CLSM Leica software,
we quantified the ERa-nucleoli recruitment by the peptides,Figure 2. CLSM Imaging of U2OS Cells after
Incubation with Biotinylated Peptide Probes
Cells were overnight incubated with peptides
featuring different tags and probe elements, fol-
lowed by immunolabeling with a Cy5-conjugated
anti-biotin antibody. PB = PEG-biotin; white
arrows indicate nucleoli, and scale bars represent
10 mm.
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Cellular Modulation of ERa with Synthetic PeptidesFigure 3. ERa-Binding Capacity of Syn-
thetic Peptides in U2OS Cells
(A) CLSM imaging of cells (positive events) after
transient transfection with ERa-CFP and incuba-
tion with nona-arginine peptides and estradiol
(106 M). White arrows show ERa sequestration
into the nucleoli, and scale bars represent 10 mm.
(B) Quantification of ERa-nucleoli recruitment
expressed as the ratio of the ERa-CFP fluores-
cence intensity per pixel into nucleoli versus the
nucleoplasm. Circles represent ratio values per
cell (6 % n % 19); medians are indicated by the
black line in the middle of the box plots and whose
sizes represent ± 25% of the medians (program
Profit); asterisks (*) indicate results statistically
different from the control (p < 0.01).expressed as the ratio of the CFP-ERa fluorescence intensity per
pixel at the nucleoli versus the nucleoplasm (Figure 3B). Interest-
ingly, significant ERa-nucleoli recruitment was found when cells
were incubated with all the synthetic R9 peptides, except for the
peptides mutated in their recognition motif by alanines (i.e.,
SRC-1 box2-Ala-R9 and Tif-2 Box2-Ala-R9 and the R9 alone;
Figure 3B and Table S2), showing that the nucleoli recruitment
is specifically due to the selective interaction of the peptides
with the ERa coactivator binding surface via their LXXLL motifs.
The ERa-nucleoli recruitment is concentration dependent
(Figure S1A), in line with the expected molecular mechanism of
the interaction. Additionally, a Tif-2 Box2 peptide not featur-
ing the R9-motif does not show ERa-nucleoli recruitment (Fig-
ure S1B), as expected on the basis of the nonnucleoli localization
of this peptide.
Among the peptides tested, the highest ERa relocation score
was found for the SRC-1 Box2-R9, Tif-2 Box1-R9, and D2-R9
peptides, with median ratios of ERa signal into the nucleoli
versus the nucleoplasm of 1.2, 0.9, and 0.8, respectively
(Figure 3B). These cellular observations are in line with our
biochemical binding results (Figure 1B) andwith previous reports
indicating that ERa interacts with all three LXXLL motifs of theChemistry & Biology 1SRC-1 coactivator but has a distinct preference for the second
motif (Voegel et al., 1998). Although no binding was observed
in our biochemical assay between the ERa LBD and the peptides
SRC-1 Box1-R9, Tif-2 Box3-R9, and D11-R9 (IC50 >300 mM),
these peptides did induce a weak but significant ERa-nucleoli
recruitment (Figure 3B). This finding underlines the value of
assessing ERa-peptide binding directly in cells, where ERa is
expressed as full length and reveals ERa-LXXLL-peptide interac-
tion surfaces beyond the isolated and not posttranslational
modified LBD alone.
Displacement of SRC1 and Tif-2 Coactivators
by LXXLL Molecular Probes in ERa Binding
To investigate whether the LXXLL-peptide-ERa binding can
displace overexpressed full-length coactivators in living cells,
we tested the ERa binding of the synthetic molecular LXXLL
probes again, but now in the presence of the transfected SRC-1
and Tif-2 coactivators, tagged with yellow fluorescent protein
(YFP). ERa indeed still colocalized with the nona-arginine
peptides into the nucleoli (Figure 4A) except for the Tif-2 Box3-
R9, R9, and the alanine mutant peptides (Table S2). We also
observed that the full-length SRC-1 coactivator could at leastFigure 4. ERa-Binding Capacity of Syn-
thetic Peptides in U2OS Cells in the Pres-
ence of Overexpressed Coactivators
(A) CLSM imaging of cells (positive events) trans-
fected with ERa-CFP and SRC-1-YFP, in the pres-
ence of estradiol (106 M). Scale bars represent
10 mm.
(B) Quantification of ERa-nucleoli recruitment in
cell cotransfected with SRC-1-YFP expressed as
the ratio of the ERa-CFP fluorescence intensity
per pixel into nucleoli versus the nucleoplasm.
Circles represent ratio values per cell (5% n% 43).
Medians are indicated by the black line in the
middle of the box plots, whose sizes represent ±
25% of the medians (program Profit). Asterisks (*)
indicate results statistically different from the
control (*p < 0.01).6, 702–711, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 705
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Transactivation by Synthetic Nona-Arginine
LXXLL Peptides
(A) U2OS cells were transfected with ERa and the
ERa-DNA binding sequence ERE-tk-Luc. Lucif-
erase activities are expressed as the ratio of Firefly
luciferase signal toRenilla luciferase signal and are
normalized to the ratio obtained when cells were
solely treated with the R9-tag peptide.
(B) Inhibition by R9 peptides of an endogenous ER-
mediated pS2 gene in MCF-7 cells. MCF-7 cells
were cultured with 70 mMof the indicated peptides
in the presence of 10 nM estradiol (E2) (unless indi-
cated). Cells were lysed after 3 hr of estradiol treat-
ment, after which RNA was isolated and prepared
for QPCR analysis of endogenous ER-mediated
pS2 mRNA levels (normalized). Error bars repre-
sent mean ± standard error.partially be recruited to the nucleoli together with ERa in cells
treated with the most potent ERa-binding peptides (data not
shown). This could be due to the recruitment of ERa as a dimer
to the nucleoli in which one monomer is bound to an arginine-
tagged peptide and the other monomer is still bound to SRC-1,
or to the ligand-independent interaction between SRC-1 and
the AF-1 domain of ERa (Webb et al., 1998; Zwart et al.,
2007a). Among the set of peptides tested, the strongest nucleoli
recruitment effect for ERa was observed with the Tif-2 Box2-R9
peptide (median ratios, 2) and the SRC-1 Box2-R9 peptide
(median ratios, 0.7) (Figure 4B), with 95% and 88% of cells,
respectively, exhibiting a ratio higher than that found for cells
treated with the control peptide R9 (Figure S2).
Similar experiments performed on cells cotransfected with
CFP-ERa and full-length YFP-Tif-2 coactivator followed by treat-
ment with the synthetic SRC-1 Box2-R9 or Tif-2 Box2-R9
peptides showed that these peptides could also efficiently
recruit ERa into the nucleoli in the presence of Tif-2 coactivator
(Figure S3). It is interesting to note that ERa nucleoli-recruitment
upon the Tif-2 Box2-R9 peptide treatment was found to be less
efficient when cells expressed the corresponding Tif-2 coactiva-
tor (median ratios, 0.6) than the SRC-1 coactivator (median
ratios, 2), possibly indicating a higher affinity of the Tif-2 coacti-
vator or a different binding mechanism.
Inhibition of ERa Gene Transactivation
by Synthetic LXXLL Motif Molecular Probes
The synthetic nona-arginine peptides induced sequestration of
ERa into the nucleoli. We therefore presumed a concomitant
decrease of ERa transcriptional activity when perturbed with
these peptides. Moreover, because these peptides are in fact
mimicking the interactions between ERa and endogenous
cofactors, we expected that they might function in a dominant
negative manner when added to cells, disrupting these interac-
tions and blocking the ERa transcriptional activity. To study
such an activity, a firefly luciferase reporter gene controlled by
EREswas cotransfected with an expression vector for ERa. Cells
were incubated in the presence or absence of estradiol, and the
reporter gene product was quantified in the resulting cell lysates
by measuring the luminescence generated from the oxyluciferin
formed (Rishi et al., 1995). All the peptides, except for the control
R9 and alanine mutant peptides, decreased ERa gene-mediated706 Chemistry & Biology 16, 702–711, July 31, 2009 ª2009 Elsevietranscription (Figure 5A). The largest inhibition, compared with
untreated cells, was obtained with the Tif-2 Box2-R9 peptide
(61.0% of inhibition), the Tif-2 Box1-R9 peptide (49.8% of inhibi-
tion), and the SRC-1 Box2-R9 peptide (48.2% of inhibition). For
comparison, when overexpressed in U2OS cells from a trans-
fected DNA construct, an SRC-1 Box2 peptide exhibited a
degree of inhibition (51.5%; Figure S4) similar to that of the
synthetic SRC-1 Box2-R9 peptide on ERa-mediated gene tran-
scription. The concentration dependence of the inhibition of
the ERa transcriptional activity by the peptides was verified
with the Tif-2 peptide constructs (Figure S5A), and no inhibition
was observed with external applied Tif-2 Box2 peptide without
an arginine tag (Figure S5B).
We also examined the effect of the most efficacious peptide
from the luciferase reporter assay (Tif-2 Box2-R9) on the expres-
sion of an endogenous ERa target gene in the breast cancer cell
line MCF-7 through quantitative polymerase chain reaction
(QPCR) analysis (Figure 5B). MCF-7 cells treated with estradiol
or with estradiol and the R9 peptide as reference showed the
expected up-regulation of ERa-mediated pS2 mRNA levels.
MCF-7 cells treated with estradiol and the Tif-2 Box2-R9 peptide
featured pS2 mRNA levels analogous to cells not treated with
estradiol, showing the effective down-regulation of the pS2
gene expression by the inhibitor peptide. Together, the results
show that inhibition of the ERa-coactivator interactions in cells
by exogenous synthetic peptides resulted in an inhibition of
ERa-mediated gene transcription, the extent of which depends
on the amino acid sequences of the peptides. There is thus
a clear relationship between the potential of the LXXLLmolecular
probes to bind and recruit ERa to the nucleoli and their capacity
to antagonize ERa-mediated gene transcription. The results
show that a cell-based study of the ERa binding and antago-
nizing activity of inhibitors directly evaluates their physiological
effects.
DISCUSSION
We have designed a set of synthetic peptidic LXXLL molecular
probes bearing both a nona-arginine tag, promoting cell-entry
and specific nucleoli localization, and a biotin tag, allowing the
visualization of their intracellular localization. Neither the arginine
tag nor the biotin epitope changed the binding affinity of ther Ltd All rights reserved
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sufficient distance from the binding pharmacophore. Even
though all the LXXLL-peptide sequences under study are
reported to have an affinity for the full-length ERa (Chang et al.,
1999; Bramlett et al., 2001), not all of the sequences were found
to bind the ERa LBD strongly. The fact that the full-length
receptor can have a different surface topology as the isolated
LBD (Chang et al., 2005; Bapat and Frail, 2003; Chang and
McDonnell, 2002) is probably reflected in these observations,
especially since a cellular activity of all these LXXLL-peptide
sequences could be shown in our studies.
In order to perform subsequent cellular studies without the
occurrence of any toxicity side effects, the concentrations at
which these probes showed cellular toxicity were determined.
Interestingly, the peptides that featured both a nona-arginine
tag and an LXXLL-motif showed higher toxicity to the cells
than either the nona-arginine tag alone or the peptide featuring
an arginine tag but with the LXXLL motif mutated to an AXXAA
motif. Since no strong differences in cellular uptake are to be
expected between the LXXLL and AXXAA peptides, the different
pharmacological behavior is more likely related to their intracel-
lular effects. This furthermore indicates that the effects observed
for the molecular probes are highly sequence specific.
CLSM imaging of cells incubated with these molecular probes
showed that they successfully entered the cells and adopted
a particular localization into the nucleoli. This particular nucleoli
localization was not found for the non-R9-tagged peptides and
is therefore exclusively due to the R9 tag. The efficient cellular
uptake and specific nucleoli localization provide a strong meth-
odological tool to study any interactions of these molecular
probes with proteins, as it can be expected that either the local-
ization of the probes or that of the proteins will be perturbed upon
binding. Transient transfection of cells with ERa together with
their incubation with the LXXLL probes showed that these
peptides indeed resulted in perturbation of the ERa through
recruitment to the nucleoli. This specific localization of ERa
was not observed for a peptide consisting of the nona-arginine
tag alone, nor was it observed for the AXXAA-motif peptides or
peptides not featuring the nona-arginine tag. The ERa recruit-
ment to the nucleoli by the nona-arginine LXXLL probes was
furthermore found to be concentration dependent. These results
show that the observed effects are due to a specific interaction
of the LXXLL motif with the ERa in combination with the localiza-
tion properties of the nona-arginine tag. The fact that the nucleoli
recruitment of ERawas observed for all the nona-arginine LXXLL
probes underlines the affinity of all these peptides for the full-
length ERa in a cellular context. The absence of this interaction
in a biochemical context for some of these peptides on the iso-
lated ERa LBD shows that cellular evaluation, as presented
here, provides a more physiologically relevant view on the
binding interaction. The binding affinity of the peptides for the
ERa can be evaluated by quantifying the ERa-nucleoli recruit-
ment. This shows that certain peptide sequences, such as
SRC-1 Box2, Tif-2 Box1, and Tif-2 Box2, show a higher affinity
than others. This is in line with observations that the ERa has
distinct preferences for the different NR boxes of coactivators
(Voegel et al., 1998).
The LXXLL probesmaintain the property to recruit the ERa into
the nucleoli even in the presence of overexpressed SRC-1 andChemistry & Biology 1Tif-2 coactivators, normally found bound to ERa in the nucleo-
plasm. The probes thus can compete with full-length coactiva-
tors in living cells. Quantification of ERa-nucleoli recruitment
upon LXXLL-peptide treatment therefore provides, to our knowl-
edge, a new, simple, and efficient method to assess the potency
of molecular probes to act as ERa-coactivator inhibitors under
physiological conditions. Among the panel of peptides tested,
the Tif-2 Box2-R9 and SRC-1 Box2-R9 peptides were found as
themost potent inhibitors of SRC-1 andTif-2 coactivator binding.
The specific physical inhibition of the ERa-coactivator interac-
tion could be correlated with a decrease in ERa transcriptional
activity when perturbed with these peptides, both in a luciferase
reporter assay and for activity of the endogenous pS2 gene
in MCF-7 cells. Again, all LXXLL probes were functional and
decreased ERa gene-mediated luciferase transcription, whereas
the control nona-arginine peptide and the AXXAA probes did not.
In line with the nucleoli recruitment results, the Tif-2 Box2 and
SRC-1 Box2 showed the strongest inhibition. The luciferase
gene transcription is inhibited to around 50% (Figure 5A). This
value is also obtained when a similar peptide is overexpressed
in U2OS cells from a transfected DNA construct and in accor-
dance with literature data on overexpressed peptides (Norris
et al., 1999; Hall et al., 2000). The Tif-2 Box2-R9 showed a
full inhibition of the pS2 gene transcription in MCF-7 cells. The
extent of the transcriptional inhibition may depend on the cell
type, assay format, and ligand-exposure time.
It was previously shown that interaction of Tif-2 with ERa is
strongly and selectively affected by mutations in NR-Box 2
(Ding et al., 1998). In a similar manner, it was shown that estra-
diol-bound full-length ERa displays unambiguous SRC-1 box
preferences for NR-Box 2, while the recruitment of boxes 1
and 3 of SRC-1 was not detected in vitro (Bramlett et al., 2001).
The 75% homology found between the SRC-1 Box2 and Tif-2
Box2 sequences provides a good explanation for the common
features, both in terms of ERa-binding capacity and ERa-medi-
ated transcription inhibition that were observed in cells for these
two peptides. Overall, there is a clear relationship between the
inhibitory effect on ERa-mediated gene transcription and ERa
translocation into the nucleoli by the molecular probes.
The mechanism of ERa inhibition by ICBs typically is via
a direct inhibition of the ERa-coativator interaction (Rodriguez
et al., 2004; Vaz et al., 2008). The nona-arginine-based inhibitors
reported here feature the same mechanism, but additionally
displace the ERa after inhibition of the ERa-coactivator interac-
tion. The mechanism of action is thus most likely a combination
of inhibition and sequestration of the receptor. The method of
cellular evaluation of inhibitory capacity on the full-length ERa
as presented here could therefore be applied to evaluate coac-
tivator binding inhibitors in general. These inhibitors could be
either provided themselves with localization and visualization
tags or be used in competition assays with themolecular peptide
probes presented here. Also, this method can provide a basis to
address NR selectivity for LXXLL-based inhibitors in a cellular
context, when applied to a panel of different NRs.
The receptor’s conformation is postulated to be a better indi-
cator of the antagonist activity of different ERa ligands than
cell-based reporter gene assays (Larson et al., 2005; Michalides
et al., 2004; Zwart et al., 2007b). Themolecular probes presented
here and derivatives thereof could provide a valuable entry to6, 702–711, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 707
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cell types. In the presence of specific ERa antagonists, the
receptor adopts a conformation that prevents coactivators from
binding (Shiau et al., 1998). It can be speculated that the molec-
ular probes presented here will not interact with this antagonist-
liganded ERa. However, in the case of antagonist resistance,
the ligand frequently acquires an agonistic function (Osborne
et al., 2003; Girault et al., 2003) and the molecular probes might
interact again with the ERa and thus induce nucleoli recruitment.
The method presented here will thus provide ways to probe the
surface of the ERa and determine its conformation in different
cell-types, dependent on ligand, orwith specificposttranslational
modifications or point mutations.
SIGNIFICANCE
The ERa-coactivator interaction, which is based on the
molecular recognition between consensus helical LXXLL
motifs of the coactivator and a hydrophobic pocket at the
surface of the receptor, is an essential step for the ERa tran-
scriptional activation process to take place. This interaction
is an important target for the development of anti–breast
cancers drugs. Here, a new, to our knowledge, chemical
biology approach is reported in which synthetic LXXLL-
peptide probes provided with specific visualization and
localization tags interact directly with ERa in cells and per-
turb its localization and transcriptional activity. These
probes monitor the affinity of specific peptide sequences
for the full-length ERa in cells. This approach represents
a significant advancement over biochemical interaction
studies, which frequently focus on the isolated ERa LBD
alone. The molecular probes feature a nona-arginine tag
that facilitates cellular entry and also accounts for specific
subcompartmental localization at the nucleoli. This specific
feature allows these probes to dislocate the ERa from the
DNA to the nucleoli upon binding and thus perturb the
assembly of the receptor transcription complex. This molec-
ular displacement of the ERa is accompanied by an inhibi-
tion of its transcriptional activity. Quantification of the
ERa-nucleoli recruitment is a simple and rapid method to
assess the affinity of peptide sequences for ERa in the phys-
iological context of a cell. Moreover, since the timing of addi-
tion and concentration are easily controlled and their amino
acid sequences can be fully modified, these arginine-tagged




The synthesis of all peptides was performed on solid support, using the Fmoc
strategy. Biotin-PEG Nova Tag resin (0.48 mmol/g, Novabiochem) was
allowed to swell in dimethylforamide (DMF) at room temperature for 30 min.
After DMF was drained, the beads were incubated with 40% piperidine in
DMF for the deprotection of the Fmoc group, and subsequently the amino
acids (AA) were introduced using the following coupling conditions: AA
(3 eq), 2-(6-chloro-1H-benzotriazole-yl)-1,1,3,3-tetramethylaminium hexa-
fluorophosphate (3 eq), and N-methylmorpholine (6 eq) in DMF for 40 min.
The Fmoc deprotection and introduction of amino acids was repeated until
the complete sequence was assembled.708 Chemistry & Biology 16, 702–711, July 31, 2009 ª2009 ElsevierThe resin was washed 5 times with dichloromethane and ether successively
and dried under vacuum for at least 1 hr. Cleavage of side chain protecting
groups and of the peptides from the resin was achieved by shaking the resin
in a mixture of trifluoroacetic acid (TFA), triisopropyl silane, ethane-1,2-dithiol,
and H2O (95/1/2.5/1.5) for 2 hr. Then, the resin was removed by filtration and
washed twice with TFA. Most of the TFA was evaporated from the combined
filtrates, and a 10-fold volume excess of cold diethyl ether was added drop-
wise to achieve peptide precipitation. The crude peptides were isolated by
centrifugation (3500 rpm, 10 min), washed with cold ether, taken up in water
and lyophilized, and finally purified by reverse-phase high-performance liquid
chromatography on a nucleodur C18 Gravity column (1253 21mm,Macherey-
Nagel) with a linear 60 min gradient of A (0.1% TFA in H2O) and B (0.1% TFA in
MeCN) from 10% B to 100% B and a flow rate of 20 mL/min1. After purifica-
tion, all the synthesized peptides were lyophilized and stored at 80C. The
purity of the peptides was assessed by analytical liquid chromatography–
mass spectrometry at 210 nm, 254 nm, and 280 nm using a diode array ultra-
violet/visible detector. All the nona-arginine peptides were obtained pure with
yields ranging from 13% to 41%.
In Vitro Competitive Fluorescence Polarization Assay Expression
and Purification of ERa-LBD Protein
The pET15b-ERa-LBD plasmid (gift from Bayer-Schering Pharma AG) encod-
ing the LBD of the human ERa was used as template for PCR amplification
using the primers 50-CCGGATGGATCCATGGGCAGCAGCCATCATCAT-30
and 50-CCGGATCTCGAGTTAAGTGGGCGCATGTAGGCGG-30. The PCR
product (ERa-LBD residues 302–553) was digested with BamHI and XhoI
enzymes (Fermentas) and subcloned into a pHT401 plasmid to introduce a
Strep-tag and His-tag at the N terminus of the ERa-LBD construct. This
plasmid (pHT503) was transformed into Escherichia coli Rosetta 2-DE3-placI
(Novagen) cells that were then grown in Luria Bertani medium with 100 mg/L
ampicilline and 34 mg/L chloramphenicol at 37C. At OD600nm 0.8, protein
expression was induced with 0.5 mM isopropyl-beta-D-thiogalactopyranoside
for 16–18 hr at 16C. Bacteria were then concentrated by centrifugation for
10 min at 5,000 rpm and were kept at 80C until purification. Cells lysate
chromatographywasperformedat 4Conan A¨KTApurifier using aHisTrap
HP 5 ml column (GE Healthcare) pre-equilibrated with the protein extract
buffer: 300mMNaCl, 50 mMNa2HPO4, 2 mMNaH2PO4, and 20mM imidazole
(pH 8.0). Protein elution was obtained with 500 mM NaCl, 50 mM Na2HPO4,
2 mM NaH2PO4, 500 mM imidazole, and 10% (v/v) glycerol (pH 8.0); fractions
containing the ERa-LBD protein were then desalted on a Sephadex G25
PD-10 column (Amersham Biosciences) pre-equilibrated with 25 mM NaCl,
20 mM Tris-HCl (pH 8.0), 10% (v/v) glycerol, and 1 mM tris (2-carboxyethyl)
phosphine.
Fluorescence Polarization Measurements
A reaction mixture containing a fluorescein-labeled coactivator (SRC-1 Box2)
peptide FL-CQLLTERHKILHRLLQEGSPSD (108 M), the ERa-LBD protein
(106 M), and estradiol (105 M) was prepared. Fluorescence polarization inhi-
bition experiments were performed in 384-well plates (Optiplate-384 F, Perkin
Elmer) by adding 10 ml of the reaction mixture to 40 ml of inhibitor peptides at
increasing concentrations. After 2 hr of incubation at 4C, the fluorescence
polarization of the labeled coactivator peptide wasmeasured on a plate reader
fluorometer (Safire2TM, Tecan) with excitation at 470 nm and emission at
519 nm for fluorescein. The concentration of inhibitor peptide that resulted
in a half-maximum decrease in the polarization value of the fluorescent coac-
tivator peptide displayed from the purified ERa was defined as IC50 and was
determined from three independent experiments with the ORIGIN 7 program
(Scientific Graphing and Analysis Software, OriginLab Corp).
Cell-Viability Assay
U2OS cancer cells (human osteosarcoma; ATCC number HTB-96) were split at
25% confluence in 96-well plates and maintained at 37C under 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% (v/v)
antibiotics penicillin/streptomycin (GIBCO) and 10% heat-inactivated fetal
calf serum (GIBCO). After 1 day, cells were incubated with 100 ml of increasing
concentrations of peptides (range from 0.01 to 5 g/L) directly diluted in the
complete medium, for 14 hr. Subsequently, 10 ml of the cell proliferation
reagent WST-1 was added to each well, and cells were incubated again inLtd All rights reserved
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the samples was then measured using a microplate reader (Safire2TM, Tecan)
at 450 nm, and cell toxicity was expressed as the percentage of inhibition of
WST-1 incorporation, compared with control cells not treated with peptides.
All cell experiments were further performed at peptide concentrations that
did not induce more than 20% of cell toxicity.
Cell Imaging by Confocal Laser Scanning Microscopy (CLSM):
Cellular Localization of the Synthetic Peptides
U2OS cells were cultured on coverslips for 48 hr before imaging in the same
complete medium as mentioned above. Fourteen hours before imaging, cells
were incubated with peptides at the nontoxic peptide concentrations
described above and then were fixed with 4% paraformaldehyde in PBS for
10 min at room temperature. A 10-min treatment of the fixed cells by PBS-
NH4Cl 50 mM and then PBS-Glycine 20 mM was used to avoid self-fluores-
cence bleaching. Cells were permeabilized with Triton X-100 0.1% for
10 min, washed 3 times, and incubated for 30 min with a blocking solution
of PBS-BSA 0.1%. The cellular distribution of peptides was revealed after
immunolabeling of the cells using a Cy5-conjugated monoclonal mouse anti-
biotin antibody (Jackson ImmunoResearch) diluted 1:400 in PBS and their
CLSM imaging (Leica TCS SP2), with the following settings: lex = 633 nm
and lem = 650–700 nm.
Cellular Assessment of ERa-LXXLL-Peptides Binding
U2OS cells were cultured on coverslips in a 6-well plate for 48 hr before
imaging in DMEM without phenol red supplemented with 1% penicillin/strep-
tomycin and 10% hormone-depleted (charcoal/dextran treated) and heat-
inactivated fetal calf serum (Thermo Scientific HyClone). At 50%of confluence,
U2OS cells (neither expressing ERa nor ERb) (Monroe et al., 2003) were tran-
siently transfected by PEI (Polysciences) or Fugene 6 (Roche) with 1 mg of
pcDNA3.1 plasmid containing theHA-ERa-CFP construct (Zwart et al., 2007a).
Cells were incubated overnight with the nona-arginine peptides dissolved in
the culturing medium. Afterward, estradiol was added to the cultures at a final
concentration of 106 M for 3 hr. Cells were then fixed and stained as
described above and imaged by CLSM (objective X63) with the followed
independent settings: lex = 458 nm and lem = 470–500 nm for CFP, and
lex = 633 nm and lem = 650–700 nm for Cy5.
The quantification of ERa-CFP in the nucleoli was performed with the Quan-
tify Histogram module within the CLSM Leica software. First, on the basis of
Cy5 fluorescence, for each cell, regions of interest (ROIs) were designed,
encompassing the nucleoli containing peptides and the nucleoplasm. Then,
the average CFP fluorescence intensity per pixel in the ROIs were subtracted
by the fluorescence intensity of the background to calculate the enrichment of
ERa-CFP in the nucleoli compared to the nucleoplasm as the mean ratio (CFP
intensity nucleoli/CFP intensity nucleoplasm). Results are presented as the
ratios (nucleoli/nucleoplasm) found per peptide for two independent experi-
ments, for a 10–20 cell population.
Cellular Assessment of LXXLL Peptides/Coactivators
(SRC-1 and Tif-2) Competitive Binding for ERa
U2OS cells were cultivated and treated in the same conditions as above and
transiently cotransfected with 1 mg of pcDNA3-ERa-CFP plasmid and 2 mg
of pcDNA3-SRC-1-YFP plasmid or 2 mg of pcDNA3-YFP-Tif-2 plasmid. After
cells were fixed and labeled with the Cy5-conjugated anti-biotin antibody,
they were imaged by CLSM with the successive settings of CFP, Cy5, and
YFP (lex = 514 nm and lem = 525–550 nm). The same method as described
above was used to quantify ERa-CFP fluorescence into the nucleoli and was
compared to the one found in the cytoplasm.
Inhibition of ERa-Mediated Gene Transcription ERa Luciferase
Transactivation Assay
U2OS cells were split in 24-well plates and maintained at 37C under 5% CO2
in Dulbecco’s modified Eagle’s medium (DMEM) without phenol red, supple-
mented with 1% (v/v) antibiotics penicillin/streptomycin and 10% hormone-
depleted and heat-inactivated fetal calf serum (Thermo Scientific HyClone).
After 1 day, cells were transfected using PEI with 10 ng of pCMV-HA-ERa
full length, 200 ng of pERE-tK-firefly luciferase (Bindels et al., 2002), and
2 ng of SV40 Renilla reniformis luciferase plasmids. After DNA transfection,Chemistry & Biology 1cells were maintained at 37C under 5% CO2 for 4 hr before treatment with
synthetic peptides directly dissolved in the medium. For comparison, a
pcDNA3.1 plasmid encoding for the SRC-1 Box2 peptide sequence (pSF5
vector) was also tested: cells were transfected with 20 ng of pSF5, 0.2 ng of
pCMV-HA-ERa, 200 ng of pERE-tK-firefly luciferase, and 2 ng of SV40 Renilla
luciferase plasmids. Four hours after adding the peptides, estradiol (108 M)
was incubated with the cells for 16 hr before the reading of firefly luciferase
expression by a dual-luciferase reporter assay system (Promega). Lumines-
cent intensities were recorded on a Berthold Centro XS3 LB 960 (Berthold
technologies). Firefly luciferase activity signal was first normalizedwith respect
to the constitutive R. reniformis luciferase signal and second normalized to the
luciferase activity found in control cells incubated with the R9 tag alone.
Results shown are representative of three independent experiments.
pS2 Gene Inhibition in MCF-7 Cells
For quantitative RT-PCR in MCF-7 cells, cells were cultured in phenol red–free
DMEMcontaining 5% charcoal-treated serum for 72 hr prior to the onset of the
experiment in order to deplete activated ER in the cells. Subsequently, cells
were cultured overnight in the presence of the indicated peptides at a final
concentration of 70 mM. After overnight treatment, 10 nM estradiol was added
for 3 hr or the cells were left untreated. After exposure to hormones, cells were
lysed, and RNAwas extracted using Trizol (Invitrogen), according to themanu-
facturer’s protocol. RNA was reverse-transcribed using SuperScript(tm) III
Reverse Transcriptase (Invitrogen), on which QPCR was performed using
CYBR Green (Applied Biosystems), according to the manufacturer’s proto-
cols. The pS2 cDNA was amplified with the forward primer 50 CATCGAC
GTCCCTCCAGAAGA and the reverse primer 50 CTCTGGGACTAATCACCG
TGCT. As a control for equal loading, the observed signals were related to
b-actin RNA levels, using a forward primer 50 CCTGGCACCCAGCACAAT
and reverse primer 50 GGGCCGGACTCGTCATACT. Input levels were related
to b-actin house keeping gene mRNA levels. Average values and SD were
obtained for samples without peptide (duplicate) or with peptide (triplicate).
SUPPLEMENTAL DATA
Supplemental data include two tables and five figures and can be found with
this article online at http://www.cell.com/chemistry-biology/supplemental/
S1074-5521(09)00207-5.
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